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ABSTRACT 
The aim of this study was to determine the effect of different concentrations of normobaric oxygen 
(NBO) on neurological function and the expression of caspase-3 and -9 in a rat model of acute cerebral 
ischaemia. Sprague-Dawley rats (n=120) were randomly divided into four groups (n=30 per group), 
including 3 groups given NBO at concentrations of 33%, 45% or 61% and one control group given air 
(21% oxygen). After 2 hours of ischaemic occlusion, each group was further subdivided into six 
subgroups (n=5) during reperfusion according to the duration (3, 6, 12, 24, 48 or 72 hours) and 
concentration of NBO (33%, 45% or 61%) or air treatment. The fluorescence quantitative Polymerase 
Chain Reaction (PCR) and immunohistochemistry were used to detect caspase-3 and -9 mRNA and 
protein relative expression respectively. The Neurologic Impairment Score (NIS) was significantly 
lower in rats given 61% NBO ≥3 hours after reperfusion when compared to the control group (P <0.05, 
Mann-Whitney U). NBO significantly reduced caspase-3 and -9 mRNA and protein expression when 
compared to the control group at all NBO concentrations and time points (P <0.05, ANOVA). The 
expression of caspase-3 and -9 was lower in the group given 61% NBO compared any other group, and 
this difference was statistically significant when compared to the group given 33% NBO for ≥48 hours 
and the control group (both P<0.05, ANOVA).  These findings indicate that NBO may inhibit the 
apoptotic pathway by reducing caspase-3 and -9 expression, thereby promoting neurological functional 
recovery after stroke. 
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1.   Introduction 
Stroke is a major international health problem and a leading cause of death and disability in developed 
countries (Donnan et al, 2008). In Western countries approximately 80% of strokes are ischaemic, 
whereas in China around 69% are ischaemic compared to haemorrhagic strokes (Go et al., 2013; Hill., 
2009; Li et al., 2008). Insufficient blood supply can result in brain ischaemia leading to white matter 
and grey matter cell death. It is clear that an increase in oxygen supply to the anoxic region can reduce 
the extent of neurological cell death (Sunami et al., 2000). Indeed, the principle aim of treating brain 
ischaemia in clinical practice is to improve blood circulation to the brain and increase blood and 
oxygen to the ischaemic penumbra, a vulnerable but potentially viable area of damaged brain cells 
surrounding the stroke core (Heiss and Graf., 1994). 
 
As a clinical treatment hyperbaric oxygen (HBO) has been proposed to improve brain metabolism, 
reduce blood brain barrier permeability, brain oedema, intra-cranial cerebral perfusion, neuroplasticity 
and apoptosis both in animals and humans with ischaemic stroke (Efrati et al., 2013; Hu and Wang., 
2013). However, HBO can also result in oxygen toxicity and the high pressure can cause damage to 
ears, eyes, lungs and increase the risk of pneumothorax and air embolism. HBO also requires 
hyperbaric chambers that cannot be easily used in acute stroke patients’ given thrombolysis and require 
intensive monitoring. In comparison, normobaric oxygen (NBO) is less expensive, convenient to use, 
and is often routinely equipped at the patient’s bedside without special conditions. A recent randomized 
controlled trial suggests that acute stroke patients given NBO at concentrations <33% started within 24 
hours of hospital-admission and given for 72 hours may slightly improve neurological recovery at 1 
week (Roffe et al., 2011). However, a quasi-randomized study conducted by Ronning and Guldvog 
(1999) found that when <33% NBO is given to non-hypoxic patients with minor or moderate strokes it 
may actually increase mortality. As such controversies still remain, oxygen supplementation is not 
recommended as a routine treatment in either Chinese or International stroke guidelines, unless oxygen 
saturation is <95% or patients have clinical signs of hypoxia (National Stroke Foundation., 2010).  
 
It has been suggested the giving NBO at high concentrations may be more beneficial to the survival of 
the ischaemic penumbra. Several studies have shown that NBO treatment given at concentrations of 
90% to 100% in rat models of transient focal cerebral ischaemia can reduce the size of the cortical 
infarct (Liu et al., 2006; Singhal et al., 2002; Yuan et al., 2010). Furthermore, brief episodes of 100% 
NBO does not appear to promote neurological damage in experimental stroke (Sun et al., 2014). High 
concentrations of HBO and/or NBO (80%-100%) have also been associated with reducing the 
occurrence of apoptosis via the cysteine-aspartic proteases (caspase) dependent apoptotic pathways 
(Akpan and Troy., 2013; Singhal and Lo., 2008). It is known that hypoxia can reduce 
adenosine-triphosphate (ATP) and release cytochrome C (Akpan and Troy., 2013). The latter is a 
caspase activating cofactor, which can promote cell death (Cho and Toledo-Pereyra., 2008). It has been 
suggested that high concentrations of oxygen could slow down death of the ischaemic cells in the 
penumbra region by inhibiting this caspase-apototic pathway (Singhal and Lo., 2008). Of the 8 types of 
caspases associated with ischaemic stroke, caspase-3 and -9 expression are found in rat controls (Geng 
et al., 2013; Zhang et al., 2004; Zhang et al., 2010). Caspase-3 is an important cysteine protease in the 
cell apoptosis process of the caspase cascade “waterfall”, and the effector molecule of performing DNA 
fragmentation that can induce cell apoptosis directly. Caspase-9 is activated by an apoptosis protease 
activator -1, a compound that is formed with cytochrome C. The activated caspase-9 then cleaves and 
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activates caspase-3 thereby inducing the cell to enter the irreversible death process (Sugawara et al., 
2004). Recent research suggests that this process may be reversed with high concentrations of 
95%NBO to reduce brain swelling in ischaemic stroke rat models (Jin et al, 2014).  However, there 
are safety concerns with giving very high concentrations of NBO (80% to 100%) as it can lead to 
hyperoxia, resulting in acute lung injury, toxicity and poor outcomes after stroke (Cornet et al, 2013; 
Huang et al., 2009; Zhou et al., 2006).  
 
The aim of this study is to determine whether NBO given at medium concentrations (33%, 45%, 61%), 
which may be better tolerated by stroke patients, and given over various time points could reduce 




2.  Results 
2.1.  NBO improved Neurologic Impairment Scores 
During reperfusion the rats’ nerve function were checked prior to and after NBO or air treatment via 
Neurologic Impairment Scores (NIS) assessment. Before NBO treatment the median NIS = 2 in all 24 
groups. Table 1 shows that the median NIS after NBO treatment was lower in rats receiving 33% NBO 
≥72 hours, 45% NBO ≥6 hours and 61% NBO ≥3 hours when compared to baseline measurements (1 
versus 2). Compared to the control group, the NIS was lower at 45% and 61% NBO at ≥48 hours 
(P=0.022, Kruskal Wallis) and in all NBO treatment groups at 72 hours (P=0.018, Kruskal Wallis)  
 
2.2.  NBO reduced caspase-3 and caspase-9 mRNA and protein expression  
The mRNA expression levels of caspase-3 and -9 in brain at different time points in all groups were 
checked via Real-time Fluorescent Quantitative PCR analysis. The mRNA expression of caspase-3 
(Fig.1a) and caspase-9 (Fig.1b) were significantly lower in NBO treatment groups when compared to 
the control group regardless of NBO concentration or duration (all P<0.01, ANOVA). The mRNA 
expressions for caspase-3 and -9 were lower in the group given 61% NBO compared to 33% and 45% 
NBO, but it was statistically significant when compared to the group given 33% NBO, regardless of 
duration (all P<0.05, ANOVA). 
The protein expression levels of caspase-3 and -9 in the ischaemic penumbra in the control group and 
NBO treatment groups were determined via indirect immunohistochemical assay. The localization of 
caspase in the ischaemic penumbra was indicated by brown staining (Fig.2a, Fig.3a). The protein 
expression of caspase-3 and -9 positive cells gradually reduced at all concentrations of NBO (Fig.2b, 
Fig.3b) and these differences were statistically significant when compared to the control group (all 
P<0.05, ANOVA). Comparing the treatment groups, protein expression was significantly lower at 61% 
NBO compared to 33% NBO, regardless of NBO duration (P<0.05, ANOVA).  
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3.  Discussion 
The results of this study found that in all NBO treatment and the control groups, caspase-3 and -9 
mRNA and protein expression increased in the ischaemic rat brain over time (3 to 72 hours). However, 
medium concentrations of NBO reduced the level of caspase-3 and -9 at all time points and was lowest 
in the group given 61% NBO. Interestingly, we also found that neurological impairment was lower at 
earlier time points as NBO concentration increased. In particular we found that the lowest NIS 
occurred in the 61% NBO group from 3 to 72 hours. This was noticeably different to the control group 
(oxygen 21%) who had the highest levels of caspase -3 and -9 and worsening of the neurological 
impairment over time. Therefore, these results support the view that neuroprotection can be achieved 
by increasing concentrations of oxygen to the ischaemic penumbra (Singhal., 2006). Our results also 
suggest that longer NBO exposure at medium concentrations may yield some benefit to improving 
neurological recovery after stroke, but whether it is sustainable due to the evolving apoptosis processes 
still remains to be determined. 
  
By using a rat model of focal cerebral ischaemia we have been able to provide further understanding of 
the apoptosis pathway after stroke. A previous study found that giving 95% NBO therapy in an 
ischaemic rat model reduced caspase-9, but they did not find a significant reduction in caspase-3 (Jin et 
al., 2014).  However, rats were exposed to NBO for only 90 minutes during middle cerebral artery 
occlusion, which may not have been long enough to detect the reduction in caspase -3, which occurs 
downstream from caspase-9 after the cytochrome c-dependent cascade is initiated (Sugawara et al., 
2004). It is also difficult to compare our results to previous experimental studies due to the differences 
in the initiation and exposure to NBO treatment after cerebral ischaemia. Indeed, the majority of these 
studies have focused on giving NBO at very high concentrations (80-100%) for shorter durations (2-12 
hours) (Singhal et al., 2002, 2006; Liu et al., 2006; Esposito et al., 2013). However, there are concerns 
that very high concentrations of NBO will generate oxygen free radicals causing worsening of the 
neurological injury (Cornet et al., 2013).  Certainly, a recent randomized controlled trial that 
investigated the effects of high flow (30-45 litres per minute) NBO (100%) given to acute stroke 
patients for 8 hours was terminated early due to excess mortality in the NBO group when compared to 
the group on air/low flow oxygen (40% versus 17%) (Singhal., 2014).  However, preliminary findings 
from the largest NBO stroke trial to date, found no benefit with lower concentrations of NBO (24-32%) 
given up to 72 hours in 8000 acute stroke patients (Roffe et al., 2014 a, b). Thus medium 
concentrations of 61% NBO may be safer and better tolerated by acute stroke patients than high NBO 
concentrations, but are possibly more effective than lower NBO concentrations at reducing short-term 
neurological impairment. However, its efficacy particularly in terms of improving longer-term 
outcomes would need to be confirmed in a clinical trial. 
 
There are a number of limitations. Firstly, experimental studies are limited by small sample sizes (n=5 
per group), however we were able to detect statistically significant differences between the 
experimental groups and the control. Second, rat models of focal cerebral ischaemia are subject to 
tightly controlled laboratory conditions and include young healthy animals, which often limits its 
applicability to stroke patients (Casals et al., 2011). Third, the timing of NBO delivery was started 2 
hours after ischaemia/reperfusion, whereas in contrast oxygen is not usually started for up to 6-72 
hours after stroke onset in human studies (Ronning et al., 1999; Padma et al., 2010; Singhal., 2014; 
Roffe., 2014a). Fourth, we did not measure the apoptosis effects of NBO once it was discontinued, but 
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there is evidence to suggest that the benefits of NBO to salvageable tissue may be lost within 24 hours 
if discontinued (Henniger et al, 2006).  Finally, it must be acknowledged that caspase -3 and -9 are not 
absolute in the apoptosis pathway and apoptosis may progress even when caspases are inhibited (Ferrer 
et al, 2003). Therefore, we recommend that future studies of caspases are considered in conjunction 
with other apoptosis assays common after stroke. 
 
In conclusion, the benefits of NBO on caspase -3 and -9 are dependent on factors such as the 
concentration and duration of NBO, which appears to have neuroprotective benefits for 
ischaemia-reperfusion injury in rat brain. We also feel that further experimental research is warranted to 
ensure the design of safe and effective randomized controlled trials for stroke patients. Future studies 
should pay particular attention to the timing of NBO delivery after stroke onset/reperfusion status and 
the longer-term effects of hyperoxia on the apoptosis pathway once NBO is discontinued.  
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4.   Experimental Procedures 
4.1 Animals 
Adult Male specific pathogen free (SPF) level Sprague–Dawley rats (n= 120, 250~300 g) were used for 
this study (experimental animal center of Zhengzhou University, license No.: SCXK (Henan) 
2010-0002). They were housed in SPF laboratory cages in a controlled environment (22.0~24.0°C) and 
were maintained under a 12/12 h light/dark cycle with free access to food and water. The “Laboratory 
Animal Care and Use Committee” at the University of Zhengzhou approved all experimental protocols.  
4.2 Experimental focal cerebral ischaemia and Neurologic Impairment Scores (NIS) 
The rats were anesthetized with 10% chloral hydrate (0.35ml/100g) by intra-peritoneal injection. A 
heating pad was used to maintain the rats’ body temperature at 37±0.5°C. An intraluminal suture 
blocked the origin of the middle cerebral artery, occluding blood flow from the internal carotid artery 
(Longa et al., 1989). The incision was closed, leaving 1 cm of the suture protruding so it could be 
withdrawn to allow reperfusion 2 hours later. All rats’ neurologic examinations were scored prior to and 
after NBO/air using a five-point scale: 0 = no neurological deficits; 1 = failure to extend left forepaw 
fully; 2 = circling to the left; 3 = falling to the left; 4 = no spontaneous walking and loss of 
consciousness (Longa et al., 1989). 
4.3 Experiment groups and NBO treatment 
The 120 rats were randomly allocated to three main experimental groups and exposed to 33%, 45% and 
61% NBO respectively or the control group that was exposed to room air only (n=30 per group).  
After 2 hours of ischaemic occlusion, each group was further subdivided into six subgroups (n=5) and 
given NBO/air for either 3, 6, 12, 24, 48 or 72 hours during reperfusion. NBO/air was given to the rats 
in a closed chamber (50cm × 30cm × 30cm) with two 1cm holes connected to the outside, one side 
with oxygen cylinder and nitrogen cylinder, and the other with the oxygen sensor used to monitor the 
oxygen concentration in the chamber. 
4.4 Real-time Fluorescent Quantitative polymerase chain reaction (PCR)  
At the end of their NBO or air treatment, the rats in each group were deeply anesthetized with 
excessive 10% chloral hydrate. The brain of the rats were removed and placed into liquid nitrogen for 
the analysis of Fluorescent Quantitative PCR. Fluorescence quantitative PCR primers, fluorescent dye 
and reference GAPDH was synthesized using RNase-free DNase 1 (TaKaRa limited company, Dalian, 
China). Following the manufacturer’s protocol, total RNA was prepared from the ischaemic tissue 
using the TRI®zol RNA isolation kit (Invitrogen, Sweden). The RNA was then resuspended in 10μl of 
nuclease free water and was measured at 260 and 280 nm using a spectrophotometer (Eppendorf 
PhysioCare Concept, Germany), All values were within 1.8-2.0, with no genomic DNA contamination. 
The RNA were adjusted for transcription of cDNA (Takara biotechnology, Dalian). The target gene 
information is in table 2. 
 
The cDNA for the real-time PCR reactions was created in a total volume of 20μl as per the 
manufacturer’s instructions (TaKaRa biotechnology, Dalian, China). Amplification reactions were 
performed using a 7500 fast Real-Time PCR System (Applied Biosystems, Massachusetts, USA) using 
the following cycling conditions: 1 cycle at 95 ℃ 30seconds (s); 40 cycles at 95 ℃ 3s and 60 ℃ 30s; 1 
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cycle at 95 ℃ 15s, 60 ℃ 1min, 95 ℃ 15s and 60 ℃ 15s. We calculated the average PCR threshold cycle 
(Ct) values of three repeated reference and objective genes of each sample, then calculated the relative 
quantitative 2－△△Ct to analyze relative gene expression [△△ Ct =(target gene Ct -internal reference 
Ct)treatment group -（target gene Ct- internal reference Ct）control group+] (Tang and Jia, 2008). GAPDH was 
taken as internal reference, and the expression of control group at 3 hours was defined as 1. 
4.5 Immunohistochemistry 
The brain tissues were cut into coronal sections (4 μ m thickness), They were incubated in rabbit 
anti-caspase-3 or anti-caspase-9 polyclonal antibody (BA2142, BA0690 1:100, Wuhan Boster 
Biotechnology, Wuhan) overnight at 26℃. Immunostaining was revealed with streptoavidin -biotin 
complex (SABC, Wuhan Boster Biotechnology, Wuhan) and a chromogenic agent 3, 
3’-diaminobenzidine (DAB, Wuhan Boster Biotechnology, Wuhan). We sequentially chose 5 visual 
fields in the ischemic penumbra of each rat at 400 × magnification (Nikon Eclipse TS 100, Nikon 
Instruments, Japan). The number of caspase-3 or -3 positive cells in each field was quantified by the 
image analysis system (NIS-Elements BR 3.2, Nikon Instruments, Japan).  
4.6 Statistical analysis  
Data were analysed using SPSS for windows (version 12 SPSS Inc, Chicago, IL. 2004). Neurological 
function scores were expressed as median (interquartile range, IQR). The immunohistochemical 
positive cells numbers and 2－△△Ct were expressed as means ± standard deviations. The differences 
between groups were calculated using Kruskal Wallis and Mann Whitney U for non-paramentric 
comparisons and ANOVA and unpaired t-test for parametric comparisons. P-values < 0.05 were 
considered statistically significant. 
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Table 1:  The Median (IQR) Neurologic Impairment Scores (NIS) for each group after NBO 
treatment compared to the control group (n=5 per group) 
 
Group 3h 6h 12h 24h 48h 72h 
61%NBO 1.0 (1.0, 2.0)* 1.0 (1.0, 1.5) * 1.0 (1.0, 2.0) * 1.0 (0.5, 2.0) * 1.0 (0.5, 2.0) * 1.0 (0.5, 1.5) * 
45%NBO 2.0 (1.0, 2.0) 1.0 (1.0, 2.0)  1.0 (1.0, 2.0) * 1.0 (1.0, 2.0) * 1.0 (1.0, 1.5) * 1.0 (1.0, 2.0) * 
33%NBO 2.0 (1.5, 2.0) 2.0 (1.0, 2.0) 2.0 (1.0, 2.0) 2.0 (1.0, 2.0) 2.0 (1.0, 2.0)*  1.0 (1.0, 2.0) * 
Control  2.0 (2.0, 2.5) 2.0 (1.5, 3.0) 2.0 (2.0, 2.5) 2.0 (2.0, 2.5) 3.0 (2.0, 3.5) 3.0 (2.0, 3.0) 
x2, df=3 5.612 5.278 5.900 5.949 9.587 10.052 
P 0.132 0.153 0.117 0.114 0.022 0.018 
Note: The differences between groups were calculated using Kruskal Wallis H test and paired 
comparisons using Mann-Whitney U test, *P<0.05.   
Abbreviations:  df, degrees of freedom; IQR, Interquartile range; h, hours; NIS, Neurological 
Impairment Score; NBO, normobaric oxygen; x2, Chi-square for H-test.
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Table 2:  The gene primer sequence and product size used for GAPDH, caspase-3 and caspase-9.  
 
Gene name Oligonucleotides used for real-time PCR primer 





caspase-9 F: CTGAGCCAGATGCTGTCCCATA 176 NM-031632.1 
 R: GACACCATCCAAGGTCTCGATGTA   
caspase-3 F:GAGACAGACAGTGGAACTGACGATG 147 NM-012922.2 
 R: GGCGCA AAGTGACTGGATGA   
GAPDH F: GGCACAGTCAAGGCTGAGAATG 138 NM-017008.4 
 R: ATGGTGGTGAAGACGCCAGTA   
 
Abbreviation:  PCR, polymerase chain reaction (PCR); F, forward primer for conventional SYBR® 
Green real-time PCR; R, reverse primer for SYBR® Green real-time PCR. 
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Fig.1 The expression of caspase-3 (A) and caspase-9 (B) mRNA in the control group (air, oxygen 
21%) and NBO treatment groups (33%, 45%, 61%) at all time points: 3h, 6h, 12h, 24h, 48h, 72h 
(n=5 per group).  
Data are expressed as mean±SD, the differences between groups were calculated using ANOVA for 
group parametric comparisons; treatment groups were compared with the control group, *P < 0.01; 61% 
and 45% NBO group compared with the 33% NBO group, #P < 0.05.  










































Fig.2 Immunohistochemistry analysis of caspase-3 for the control and NBO treatment groups. (A) 
Expression of caspase-3 in rat brain tissue at all time points: 3h, 6h, 12h, 24h, 48h, 72h (n=5 per 
group). SABC stain ×400 (Scale bar 200μm). (B) The number of caspase-3 positive cells in control 
and NBO treatment groups (n=5 per group).  
Data are expressed as mean±SD, the differences between groups were calculated using ANOVA for 
parametric comparisons; NBO treatment groups were compared with the control group, *P < 0.01; 
61% and 45% NBO group compared with the 33% NBO group, #P < 0.05. 





































Fig.3 Immunohistochemistry analysis of caspase-9 for the control and NBO treatment groups. (A) 
Expression of caspase-9 in rat brain tissue at all time points: 3h, 6h, 12h, 24h, 48h, 72h (n=5 per 
group) - SABC stain ×400 ( Scale bar 200μm).  (B) The number of caspase-9 positive cells in 
control and NBO treatment groups (n=5 per group).  
Data are expressed as mean±SD, the differences between groups were calculated using ANOVA for 
parametric comparisons; NBO treatment groups compared with the control group, *P < 0.01; 61% and 
45% NBO group compared with the 33% NBO group, #P < 0.05.  
Abbreviations: NBO, normobaric oxygen; SABC, strept avidin-biotin complex 
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